866-997-4948(US-Canada Toll Free)

United States Acinetobacter Infections Treatment Market Report 2018

Published By :

QYResearch

Published Date : Jan 2018

Category :

Healthcare IT

No. of Pages : 128 Pages

In the last several years, global market of Acinetobacter Infections Treatment developed rapidly, with an average growth rate of 2.96%. In 2016, United States Market Size of Acinetobacter Infections Treatment is nearly 22 M USD. For developing product, there are 1 in Phase III, 1 in Phase ?, 4 in Phase 1 and 8 in Preclinical. The total investment for Acinetobacter Infections Treatmen Drugs developing is around 90 M USD.

This report studies the Acinetobacter Infections Treatment development status and future trend in United States, focuses on top players in United States, also splits Acinetobacter Infections Treatment by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in United States market include 
Entasis Therapeutics
Roche 
Adenium Biotech
Vaxdyn 
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals

Geographically, this report splits the United States market into six regions, 
Northeast
South Atlantic
West South Central
East North Central
Pacific
Other


On the basis of product, the Acinetobacter Infections Treatment market is primarily split into 
Sulbactam
Carbapenems 
Aminoglycosides
Polymyxins
Tetracyclines
Others

On the basis on the Pipeline this report covers 
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small molecule antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
eCAPs
SLP0904
S-649266 (cefiderocol)
Gram Negative (AcB)
TP-6076

Table of Contents

1 Acinetobacter Infections Treatment Overview 1
1.1 Product Overview and Scope of Acinetobacter Infections Treatment 1
1.2 Classification of Acinetobacter Infections Treatment by Product Category 2
1.2.1 United States Acinetobacter Infections Treatment Revenue Comparison by Types (2012-2023) 2
1.2.2 United States Acinetobacter Infections Treatment Revenue Market Share by Types (Product Category) in 2016 3
1.2.3 Sulbactam 3
1.2.4 Carbapenems 4
1.2.5 Aminoglycosides 4
1.2.6 Polymyxins 5
1.2.7 Tetracyclines 6
1.3 United States Acinetobacter Infections Treatment Market by Pipeline 7
1.4 United States Acinetobacter Infections Treatment Market by Regions 8
1.4.1 United States Acinetobacter Infections Treatment Market Size (M USD) Comparison by Regions (2012-2023) 9
1.4.2 Northeast Acinetobacter Infections Treatment Status and Prospect (2012-2023) 10
1.4.3 South Atlantic Acinetobacter Infections Treatment Status and Prospect (2012-2023) 11
1.4.4 West South Central Acinetobacter Infections Treatment Status and Prospect (2012-2023) 12
1.4.5 East North Central Acinetobacter Infections Treatment Status and Prospect (2012-2023) 13
1.4.6 Pacific of US Acinetobacter Infections Treatment Status and Prospect (2012-2023) 14
1.5 United States Market Size (Sales and Revenue) of Acinetobacter Infections Treatment (2012-2023) 15
1.5.1 United States Acinetobacter Infections Case and Growth Rate (2012-2023) 15
1.5.2 United States Acinetobacter Infections Treatment Revenue and Growth Rate (2012-2023) 16

2 United States Acinetobacter Infections Treatment Market Competition by Players/Manufacturers 17
2.1 United States Acinetobacter Infections Treatment Pipeline of Key Players/Manufacturers in 2017 17
2.2 United States Acinetobacter Infections Treatment R&D Investment and Share by Players/Manufacturers (2016-2017) 18
2.3 United States Acinetobacter Infections Treatment R&D Investment Market Competitive Situation and Trends 21
2.3.1 United States Acinetobacter Infections Treatment Market Concentration Rate 21
2.3.2 United States Acinetobacter Infections Treatment Market Share of Top 3 and Top 5 Players/Manufacturers 22
2.4 United States Players/Manufacturers Acinetobacter Infections Treatment Headquarters, Established and Pipeline 23

3 United States Acinetobacter Infections Treatment Case and Revenue by Regions (2012-2017) 25
3.1 United States Acinetobacter Infections Case and Share by Regions (2012-2017) 25
3.2 United States Acinetobacter Infections Treatment Revenue and Market Share by Regions (2012-2017) 27
3.3 United States Acinetobacter Infections Treatment Cost by Regions (2012-2017) 29

4 United States Acinetobacter Infections Treatment Revenue by Type/ Product Category (2012-2017) 30
4.1 United States Acinetobacter Infections Treatment Revenue and Market Share by Type (2012-2017) 30
4.2 United States Acinetobacter Infections Treatment Sales Growth Rate (%) by Type (2012-2017) 33

5 United States Acinetobacter Infections Treatment Sales by Pipeline 34
5.1 United States Acinetobacter Infections Treatment Pipeline 34
5.2 United States Acinetobacter Infections Treatment Product Introduction 34
5.2.1 ETX2514 Introduction 34
5.2.2 Nacubactam RG6080 Introduction 35
5.2.3 Arenicin Introduction 35
5.2.4 VXD-001 Introduction 36
5.2.5 Small molecule antibiotic Introduction 36
5.2.6 AR-401 mAB Introduction 37
5.2.7 LCB01-0371 (PO) Introduction 38
5.2.8 GN-4474 Introduction 38
5.2.9 Antibacterial Antibody Introduction 38
5.2.10 eCAPs Introduction 39
5.2.11 SLP0904 Introduction 39
5.2.12 S-649266 (cefiderocol) Introduction 40
5.2.13 Gram Negative (AcB) Introduction 40
5.2.14 TP-6076 40

6 Analysis of Acinetobacter Infections Treatment Industry Key Manufacturers 41
6.1 Entasis Therapeutics 41
6.1.1 Company Profile 41
6.1.2 Product Information 42
6.1.3 Product, Stage and Investment 43
6.2 Roche 43
6.2.1 Company Profile 43
6.2.2 Product Information 44
6.2.3 Product, Stage and Investment 45
6.3 Adenium Biotech 45
6.3.1 Company Profile 45
6.3.2 Product Information 46
6.3.3 Product, Stage and Investment 47
6.4 Vaxdyn 47
6.4.1 Company Profile 47
6.4.2 Product Information 48
6.4.3 Product, Stage and Investment 49
6.5 Hsiri Therapeutics 49
6.5.1 Company Profile 49
6.5.2 Product Information 50
6.5.3 Product, Stage and Investment 51
6.6 Aridis Pharmaceuticals 51
6.6.1 Company Profile 51
6.6.2 Product Information 52
6.6.3 Product, Stage and Investment 53
6.7 LegoChem Biosciences 53
6.7.1 Company Profile 53
6.7.2 Product Information 54
6.7.3 Product, Stage and Investment 55
6.8 Atterx Biotherapeutics 55
6.8.1 Company Profile 55
6.8.2 Product Information 56
6.8.3 Product, Stage and Investment 57
6.9 Achaogen 57
6.9.1 Company Profile 57
6.9.2 Product Information 58
6.9.3 Product, Stage and Investment 59
6.10 Peptilogics 59
6.10.1 Company Profile 59
6.10.2 Product Information 60
6.10.3 Product, Stage and Investment 60
6.11 Sealife PHARMA 61
6.11.1 Company Profile 61
6.11.2 Product Information 62
6.11.3 Product, Stage and Investment 62
6.12 Shionogi 63
6.12.1 Company Profile 63
6.12.2 Product Information 64
6.12.3 Product, Stage and Investment 64
6.13 Techulon 64
6.13.1 Company Profile 64
6.13.2 Product Information 65
6.13.3 Product, Stage and Investment 66
6.14 Tetraphase Pharmaceuticals 66
6.14.1 Company Profile 66
6.14.2 Product Information 67
6.14.3 Product, Stage and Investment 67

7 Acinetobacter Infections Treatment Manufacturing Cost Analysis 68
7.1 Acinetobacter Infections Treatment R&D Cost Analysis 68
7.1.1 Clinical Phase Costs 69
7.1.2 Capitalized Costs 70
7.2 Proportion of Manufacturing Cost Structure 71
7.2.1 Raw Materials 71
7.2.2 Labor Cost 72
7.2.2.1 USA Labor Cost Analysis 73
7.2.2.2 Europe Labor Costs Analysis 75
7.2.2.3 Asia Labor Costs Analysis 77
7.2.3 Manufacturing Expenses 79
7.3 Manufacturing Process Analysis of Acinetobacter Infections Treatment 80

8 Industrial Chain, Sourcing Strategy and Downstream Buyers 81
8.1 Acinetobacter Infections Treatment Industrial Chain Analysis 81
8.2 Upstream Raw Materials Sourcing 82
8.3 Downstream Buyers 82

9 Marketing Strategy Analysis, Distributors/Traders 85
9.1 Marketing Channel 85
9.1.1 Direct Marketing 85
9.1.2 Indirect Marketing 86
9.1.3 Marketing Channel Development Trend 86
9.2 Market Positioning 86
9.2.1 Pricing Strategy 86
9.2.2 Brand Strategy 88
9.2.2.1 Introducing pharmaceutical branding strategies 88
9.2.2.2 Building pharmaceutical brands 88
9.2.2.3 Communicating pharmaceutical brands 89
9.2.2.4 Alternative brand models 90
9.2.2.5 The future of pharmaceutical branding 90
9.2.3 Target Client 91
9.3 Distributors/Traders List 93

10 Market Effect Factors Analysis 94
10.1 Technology Progress/Risk 94
10.2 Consumer Needs/Customer Preference Change 95
10.3 Economic/Political Environmental Change 95

11 United States Acinetobacter Infections Treatment Market Size (Sales and Revenue) Forecast (2018-2023) 104
11.1 United States Acinetobacter Infections Treatment Sales Revenue Forecast (2018-2023) 104
11.2 United States Acinetobacter Infections Treatment Market Size Forecast by Type (2018-2023) 105
11.3 United States Acinetobacter Infections Treatment Market Size Forecast by Regions (2018-2023) 107

12 Research Findings and Conclusion 109

13 Methodology and Data Source 110
13.1 Methodology/Research Approach 110
13.1.1 Research Programs/Design 110
13.1.2 Market Size Estimation 111
13.1.3 Market Breakdown and Data Triangulation 113
13.2 Data Source 114
13.2.1 Secondary Sources 114
13.2.2 Primary Sources 114
13.3 Disclaimer 115
13.4 Author List 117

List of Table

List of Tables and Figures

Figure Product Picture of Acinetobacter Infections Treatment 1
Table United States Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate Comparison by Types (Product Category) (2012-2023) 2
Figure United States Acinetobacter Infections Treatment Revenue Market Share by Types (Product Category) in 2016 3
Figure Sulbactam Product Picture 4
Figure Carbapenems Product Picture 4
Figure Aminoglycosides Product Picture 5
Figure Polymyxins Product Picture 6
Figure Tetracyclines Product Picture 7
Table United States Acinetobacter Infections Treatment Comparison by Pipeline in 2017 7
Figure United States Acinetobacter Infections Treatment Comparison by Pipeline in 2017 8
Figure United States Acinetobacter Infections Treatment Market Size (M USD) Comparison by Regions (2012-2023) 9
Figure Northeast Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 10
Figure South Atlantic Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 11
Figure West South Central Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 12
Figure East North Central Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 13
Figure Pacific of US Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 14
Figure United States Acinetobacter Infections Case and Growth Rate (2012-2023) 15
Figure United States Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate (2012-2023) 16
Table United States Acinetobacter Infections Treatment Pipeline of Key Players/Manufacturers 2017 17
Table United States Acinetobacter Infections Treatment R&D Investment (M USD) by Players/Manufacturers (2016-2017) 18
Table United States Acinetobacter Infections Treatment R&D Investment Market Share by Players/Manufacturers (2016-2017) 18
Figure 2016 United States Acinetobacter Infections Treatment R&D Investment Market Share by Players/Manufacturers 19
Figure 2017 United States Acinetobacter Infections Treatment R&D Investment Market Share by Players/Manufacturers 20
Figure 2017 United States Acinetobacter Infections Treatment R&D Investment Market Share by Players/Manufacturers 21
Figure United States Acinetobacter Infections Treatment R&D Investment Market Share of Top 3 Players/Manufacturers 22
Figure United States Acinetobacter Infections Treatment R&D Investment Market Share of Top 5 Players/Manufacturers 23
Table United States Players/Manufacturers Acinetobacter Infections Treatment Headquarters and Established 23
Table United States Players/Manufacturers Acinetobacter Infections Treatment Product Pipeline 24
Table United States Acinetobacter Infections Case by Regions (2012-2017) 25
Table United States Acinetobacter Infections Case Share by Regions (2012-2017) 25
Figure United States Acinetobacter Infections Treatment Sales Share by Regions (2012-2017) 26
Figure United States Acinetobacter Infections Treatment Sales Market Share by Regions in 2016 26
Table United States Acinetobacter Infections Treatment Revenue (M USD) and Market Share by Regions (2012-2017) 27
Table United States Acinetobacter Infections Treatment Revenue Market Share by Regions (2012-2017) 27
Figure United States Acinetobacter Infections Treatment Revenue Market Share by Regions (2012-2017) 28
Figure United States Acinetobacter Infections Treatment Revenue Market Share by Regions in 2016 28
Table United States Acinetobacter Infections Treatment Cost (USD/Case) by Regions (2012-2017) 29
Table Dosing information, Acquisition and Administration Costs 29
Table United States Acinetobacter Infections Treatment Revenue (M USD) and Market Share by Type (2012-2017) 30
Table United States Acinetobacter Infections Treatment Revenue Market Share by Type (2012-2017) 30
Figure Revenue Market Share of Acinetobacter Infections Treatment by Type (2012-2017) 31
Figure Revenue Market Share of Acinetobacter Infections Treatment by Type in 2016 32
Figure United States Acinetobacter Infections Treatment Sales Growth Rate (%) by Type (2012-2017) 33
Table United States Acinetobacter Infections Treatment Pipeline of Key Players/Manufacturers 2017 34
Table S-649266 (cefiderocol) Introduction 40
Table Entasis Therapeutics Company Profile 41
Table Acinetobacter Infections Treatment Product Introduction of Entasis Therapeutics 42
Table Product, Stage and Investment (M USD) of Entasis Therapeutics 2016-2016 43
Table Roche Company Profile 43
Table Acinetobacter Infections Treatment Product Introduction of Roche 44
Table Product, Stage and Investment (M USD) of Roche 2016-2016 45
Table Adenium Biotech Company Profile 45
Table Acinetobacter Infections Treatment Product Introduction of Adenium Biotech 46
Table Product, Stage and Investment (M USD) of Adenium Biotech 2016-2016 47
Table Vaxdyn Company Profile 47
Table Acinetobacter Infections Treatment Product Introduction of Vaxdyn 48
Table Product, Stage and Investment (M USD) of Vaxdyn 2016-2016 49
Table Hsiri Therapeutics Company Profile 49
Table Acinetobacter Infections Treatment Product Introduction of Hsiri Therapeutics 50
Table Product, Stage and Investment (M USD) of Hsiri Therapeutics 2016-2016 51
Table Aridis Pharmaceuticals Company Profile 51
Table Acinetobacter Infections Treatment Product Introduction of Aridis Pharmaceuticals 52
Table Product, Stage and Investment (M USD) of Aridis Pharmaceuticals 2016-2016 53
Table LegoChem Biosciences Company Profile 53
Table Acinetobacter Infections Treatment Product Introduction of LegoChem Biosciences 54
Table Product, Stage and Investment (M USD) of LegoChem Biosciences 2016-2016 55
Table Atterx Biotherapeutics Company Profile 55
Table Acinetobacter Infections Treatment Product Introduction of Atterx Biotherapeutics 56
Table Product, Stage and Investment (M USD) of Atterx Biotherapeutics 2016-2016 57
Table Achaogen Company Profile 57
Figure Acinetobacter Infections Treatment Product Introduction of Achaogen 58
Table Product, Stage and Investment (M USD) of Achaogen 2016-2016 59
Table Peptilogics Company Profile 59
Table Acinetobacter Infections Treatment Product Introduction of Peptilogics 60
Table Product, Stage and Investment (M USD) of Peptilogics 2016-2016 60
Table Sealife PHARMA Company Profile 61
Table Acinetobacter Infections Treatment Product Introduction of Sealife PHARMA 62
Table Product, Stage and Investment (M USD) of Sealife PHARMA 2016-2016 62
Table Shionogi Company Profile 63
Table Acinetobacter Infections Treatment Product Introduction of Shionogi 64
Table Product, Stage and Investment (M USD) of Shionogi 2016-2016 64
Table Techulon Company Profile 64
Figure Acinetobacter Infections Treatment Product Introduction of Techulon 65
Table Product, Stage and Investment (M USD) of Techulon 2016-2016 66
Table Tetraphase Pharmaceuticals Company Profile 66
Table Acinetobacter Infections Treatment Product Introduction of Tetraphase Pharmaceuticals 67
Table Product, Stage and Investment (M USD) of Tetraphase Pharmaceuticals 2016-2016 67
Figure typical phases from research to the market for a drug candidate 69
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound 70
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 71
Figure Manufacturing Cost Structure of Acinetobacter Infections Treatment 71
Figure Assessment of API Manufacturing Cost By Region 72
Figure USA Overview of Average Hourly Wages 2015-2016 (USD/Hour) 73
Figure USA Overview of Labor Costs 2013-2016 (110 Index Points) 73
Figure Cost of Employing a Factory Worker 75
Figure 2015 Estimated Labor Costs for the Whole Economy in Europe 76
Figure Monthly Minimum Wages in Asia 2016 77
Figure China Overview of Average Yearly Wages 2015-2016 (CNY/Year) 78
Figure Japan Overview of Average Monthly Wages 2015-2016(JPY Thousand/Month) 78
Table 2015 Global Electricity Price of Industry (USD/KWh) by Country 79
Figure Manufacturing Process Analysis of Acinetobacter Infections Treatment 80
Figure Acinetobacter Infections Treatment Industrial Chain Analysis 81
Table Major Buyers of Acinetobacter Infections Treatment 82
Figure Marketing Channel for Biopharmaceuticals 85
Table Some of Famous Hospital 91
Table Distributors/Traders List 93
Table Multidrug-resistant Acinetobacter in USA 94
Figure Multidrug-resistant Acinetobacter in USA 95
Figure Global GDP Growth Rate for 2016 96
Figure US GDP 2006-2016 (Billion USD) 97
Figure US CPI Change 2016-2017 97
Figure EU GDP 2006-2016 (Billion USD) 98
Figure EU CPI Change 2012-2016 98
Figure Germany GDP 2006-2016 (Billion USD) 99
Figure Germany CPI Change 2016-2017 99
Figure UK GDP 2006-2016 (Billion USD) 99
Figure UK CPI Change 2016-2017 100
Figure Italy GDP 2006-2016 (Billion USD) 100
Figure Italy CPI Change 2016-2017 101
Figure Japan GDP 2006-2016 (Billion USD) 101
Figure Japan CPI Change 2012-2016 102
Figure China GDP 2006-2016 (Billion USD) 102
Figure China CPI Change 2016-2017 103
Figure United States Acinetobacter Infections Case and Growth Rate Forecast (2018-2023) 104
Figure United States Acinetobacter Infections Treatment Revenue (M USD) and Growth Rate Forecast (2018-2023) 105
Table United States Acinetobacter Infections Treatment Market Size (M USD) Forecast by Type (2018-2023) 105
Figure United States Acinetobacter Infections Treatment Market Size Share Forecast by Type (2018-2023) 106
Figure United States Acinetobacter Infections Treatment Market Size Share Market Share Forecast by Type in 2023 106
Table United States Acinetobacter Infections Treatment Market Size (M USD) Forecast by Regions (2018-2023) 107
Table United States Acinetobacter Infections Treatment Market Size Share Forecast by Regions (2018-2023) 107
Figure United States Acinetobacter Infections Treatment Market Size Share Forecast by Regions (2018-2023) 108
Figure United States Acinetobacter Infections Treatment Market Size Share Forecast by Regions in 2023 108
Table Research Programs/Design for This Report 110
Figure Bottom-up and Top-down Approaches for This Report 112
Figure Data Triangulation 113
Table Key Data Information from Secondary Sources 114
Table Key Data Information from Primary Sources 115

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *